Association of number of comorbidities and health-related quality of life in patients with rheumatoid arthritis by Corbo, Kalaina
  
Title Page 
Association of Number of Comorbidities and Health-Related Quality of Life in Patients 

























Submitted to the Graduate Faculty of the 
 
School of Nursing in partial fulfillment 
 
of the requirements for the degree of 
 














UNIVERSITY OF PITTSBURGH 
 


















It was defended on 
 
October 22, 2020 
 
and approved by 
 
Jacqueline Dunbar-Jacob PhD, RN, FAAN, Dean and Distinguished Service Professor of 
Nursing, Office of the Dean at the University of Pittsburgh 
 
Jeffrey M. Rohay PhD, MSIS, Assistant Professor, Health and Community Systems at the 
University of Pittsburgh 
 
Karen Smarr PhD, Adjunct Assistant Professor, Medicine-Immunology & Rheumatology at 
University of Missouri Columbia 
 
Thesis Advisor/Dissertation Director: Elizabeth A. Schlenk PhD, RN, FAAN, Associate 
































Association of Number of Comorbidities and Health-Related Quality of Life in Patients 
with Rheumatoid Arthritis 
 
Kalaina Corbo, BSN 
 
University of Pittsburgh, 2021 
 
 
Rheumatoid arthritis (RA) is a progressive inflammatory disease that is associated with 
multiple comorbidities. This study investigated the association between total number of 
comorbidities and patients’ health-related quality of life represented by physical component 
summary score (PCS) and mental component summary score (MCS), while controlling for 
rheumatoid arthritis disease activity (RADAI). This study was a cross-sectional, descriptive 
correlational study and secondary analysis of existing data. A partial correlation was done for the 
associations between Total Comorbidities and PCS and MCS, while controlling for disease 
activity. The results showed that Total Comorbidities and PCS were significantly but weakly 
negatively correlated (r=-0.228, p<0.001), while Total Comorbidities and MCS were not 
significantly correlated (r=-0.041, p=0.315). When RADAI was removed as a control variable, 
the correlations between Total Comorbidities and PCS improved slightly (r=-0.314, p<0.001) 
and Total Comorbidities and MCS became significantly but very weakly negatively correlated 
(r=-0.098, p=0.017). RADAI was then investigated as both a moderating and mediating variable 
in the relationship between Total Comorbidities and PCS and MCS. RADAI was not found to be 
a moderator; however, mediation analysis showed that there was an indirect mediating effect of 
RADAI on both PCS and MCS. Increasing disease activity decreased both PCS and MCS, but 
PCS was more affected. The mediation analysis also showed that there was a significant direct 
effect of Total Comorbidities on PCS (p<0.001), but it was reduced compared to the total effect, 
which demonstrated the mediating effects of RADAI. In contrast, while the total effect of Total 
 iii 
Comorbidities on MCS was significant (p=0.0167), when the mediating effect of RADAI was 
removed, the direct effect of Total Comorbidities on MCS was not significant (p=0.3153). This 
result implies that the apparent association between Total Comorbidities and MCS was largely 
due to the mediating effect of RADAI. These results suggest that PCS is more directly affected 
by increases in comorbidities than MCS and emphasizes the importance of treating comorbidities 
as well as the RA disease in order to improve physical health-related quality of life for patients. 
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Rheumatoid arthritis (RA) is a chronic progressive systemic inflammatory disease with a 
prevalence of 1-2% of the population, and a higher prevalence in women and older adults. There 
is also an increased prevalence among first relatives suggesting some patients may have a genetic 
predisposition to this autoimmune disease. RA is marked by swelling and progressive destruction 
of joints, particularly in fingers, wrists, toes, ankles, feet, and knees. The initial pathogenesis of 
the disorder involves hyperproliferation of synovial cells in joints followed by an immune 
response from helper T-cells and other immune cells, which causes edema and 
neovascularization. The cycle of synovium proliferation and immune response eventually causes 
pannus formation, and consequentially joint destruction and ankylosis (Grossman, 2014). 
In addition to joint destruction, one of the most notable complications associated with RA 
is the prevalence of multiple comorbidities in patients. On average, patients diagnosed with RA 
have two or more extra-articular comorbidities early in the disease onset and gain additional 
comorbidities within five years of diagnosis (Innala et al., 2016). These comorbidities contribute 





Some of the common comorbidities of RA, including disturbed sleep, fatigue, and 
depression, may be a reflection of living with a chronic systemic inflammatory disease (Luyster, 
Chasens, Wasko, & Dunbar-Jacob, 2011). However, research shows that RA patients also have 
higher than expected prevalence of infections, osteoporosis, chronic obstructive pulmonary 
disease, hypertension, myocardial infarction, stroke, and specific cancers (Dougados, 2016). An 
international survey of nearly 4,000 patients found these comorbidities were higher than 
expected in RA patients, although the prevalence varied considerably between countries. The 
most common comorbidities in the 400 US patients with RA in Dougados’ study were 
hypertension (39%), hyperlipidemia (38%), depression (33%), hyperglycemia (21%), asthma 
(21%), gastrointestinal ulcer (11%), chronic obstructive pulmonary disease (8%), coronary heart 
disease (5%), and stroke (3%) (Dougados et al., 2013). For comparison, the Centers for Disease 
Control and Prevention reported that the prevalence in the general US population for this time 
period was 33% with hypertension, 29% with hyperlipidemia, 8% with depression, 14% with 
hyperglycemia, 8% with asthma, 6% with gastrointestinal ulcer, 4% with chronic obstructive 
pulmonary disease, 6% with coronary heart disease, and 3% with stroke (Brody, Pratt, & 
Hughes, 2018; National Center for Health Statistics, 2017; Syamlal, Doney, & Mazurek, 2019; 
Villarroel, Blackwell, & Jen, 2019a; Villarroel, Blackwell, & Jen, 2019b; Villarroel, Blackwell, 
& Jen, 2019c). When comparing the prevalence of comorbidities in RA patients in Dougados’ 
study to those in the general US population, there is a higher than expected prevalence (p<0.01 in 
a one-sample chi square test) in Dougados’ study for all comorbidities listed above except 
coronary heart disease (p=0.40) and stroke (p=1.00). A statistical analysis conducted in a Korean 
study found that, when adjusted for socioeconomic and lifestyle factors, Korean patients with 
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RA had a significantly increased prevalence (p<0.05) of myocardial infarction or angina, 
pulmonary tuberculosis, asthma, thyroid disease, depression, and hepatitis B compared with 
those who did not have RA (Jeong et al., 2017). 
While studies have established the higher prevalence of cardiovascular, lung, infection, 
and cancer comorbidities in RA patients than the general population, the contribution of the RA 
disease itself to the development of these comorbidities is confounded by patients’ increased age, 
prior health, lifestyle behaviors, and the medications typically used to treat RA. When comparing 
RA to the general population, there is a higher prevalence of smoking and high lipid levels prior 
to the diagnosis, which are both risk factors for future cardiac complications. In addition, some 
of the medications used to treat RA, including glucocorticoids, can increase cardiac risk by 
stiffening arteries (Crowson et al., 2013). Glucocorticoids have also been associated with 
increased risk of hyperglycemia, diabetes, osteoporosis, and infection. Other RA drugs like 
disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor inhibitors (antiTNF), 
and nonsteroidal anti-inflammatory drugs (NSAIDs) also increase susceptibility to other 
comorbidities (Roubille et al., 2015). DMARDs and NSAIDs have been associated with peptic 
ulcers and other gastrointestinal issues, and DMARDs and antiTNF drugs are associated with 
infections and cancers, such as lymphomas (Michaud & Wolfe, 2007; Young & Kaduri, 2007). 
Since a goal of RA treatment is to slow the disease progression and improve patients’ 
lives, a number of research studies have attempted to quantify and relate RA patients’ disability 
to their health-related quality of life (HRQoL) using various instruments. The degree of disability 
in RA patients has been measured by many different methods including non-disease specific 
questionnaires such as the Medical Outcomes Study Short Form-36 (SF-36), the Nottingham 
Health Profile (NHP), and Sickness Impact Profile (SIP), and more disease specific 
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questionnaires such as the Stanford Health Assessment Questionnaire (HAQ) and its modified 
versions like HAQ-II, modified-HAQ (MHAQ), and multidimensional-HAQ (MDHAQ). Visual 
analog scales (VAS) have also been used to assess physical function, pain, and fatigue. Lastly, 
performance measures like handgrip strength, walking time, and the button test have been used 
to measure disability. Some of the same instruments that capture disability can also capture 
HRQoL in RA patients, including SF-36, NHP, SIP, and VAS-fatigue. Non-disease specific 
HRQoL has also been measured using health utility scales, including the EuroQoL-5 Dimension 
(EQ-5D), Finnish 15-Dimension (15D), and Health Utilities Index Mark 2 and 3 (HUI-2 and 
HUI-3). Arthritis specific HRQoL scales have also been used in some studies, with the most 
popular being the Arthritis Impact Measurement Scale-2 (AIMS-2) and the Rheumatoid Arthritis 
Quality of Life (RAQoL) questionnaire (Lillegraven & Kvien, 2007). 
Although a number of studies have examined the effect of different drug therapies on the 
level of disability and HRQoL in RA patients, relatively few studies have examined the 
relationship of comorbidities and HRQoL in patient with RA (van Onna & Boonen, 2016), which 
is the gap in knowledge the proposed study will attempt to address. Matcham et al. (2014) 
reported results of a meta-analysis of 31 published studies using SF-36 and found that RA 
negatively affected both physical component and mental component scores of HRQoL more than 
other physical illnesses. Rupp, Boshuizen, Jacobi, Dinant, and van den Bos (2004) found that 
that fatigue, pain, and depression in RA patients were interrelated and negatively affected 
HRQoL as assessed by RAND-36, which is similar to SF-36. Luyster et al. (2011) also examined 
the interrelationships between sleep, fatigue, depression, disability, and pain, and found that poor 
sleep quality was associated with greater functional disability among patients with RA as 
determined by SF-36, with this relationship being explained by pain severity and fatigue. A 2010 
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study from Radner, Smolen, and Aletaha identified a significant inverse relationship between 
number of RA comorbidities and physical function (p<0.001). The study demonstrated that an 
increased number of comorbidities in RA patients decreased HRQoL and ability to conduct 
physical activities of daily living, such as dressing, hygiene, and eating. However, Radner et al. 
(2010) did not examine the effect of number of RA comorbidities on the mental domain of 
HRQoL. Gerhold et al (2015) stratified patients in the RABBIT database to identify HRQoL 
responders (the 22-37% of patients who had at least an 18-point increase in PCS and 22-point 
increase in MCS after 12 months of therapy). The percent of patients not meeting their PCS 
responder criteria increased as comorbidities increased; however, the effect of the number of 
comorbidities on PCS and MCS in the overall patient population was not characterized. Garip, 
Eser, and Bodur (2016) found that the presence of comorbidities in RA was associated with a 
more severe disease state and suggested that the treatment and acknowledgement of these other 
diseases should play an important role in the care of patients with RA. Although the literature 
suggests that comorbidities may worsen HRQoL for patients with RA, the association of number 
of comorbidities and the physical and mental domains of HRQoL in patients with RA has not 
been fully characterized. 
1.2 Purpose 
The purpose of this study was to explore the association of number of comorbidities and 
HRQoL in patients with rheumatoid arthritis controlling for disease activity. 
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1.3 Research Questions 
1. Is the number of comorbidities associated with the physical component summary 
score of HRQoL controlling for disease activity? 
2. Is the number of comorbidities associated with the mental component summary score 




This study was a secondary analysis of existing data from a randomized controlled trial of 
a behavioral intervention to improve medication adherence in patients with RA (NIH, R01 
NR04554, 1998-2006). The Principal Investigator of the parent study, Jacqueline Dunbar-Jacob, 
PhD, RN, FAAN, granted permission for this secondary analysis, and the University of 
Pittsburgh Human Research Protection Office (HRPO) approved the study (Appendix B). The 
design was a cross-sectional, descriptive correlational study examining the association of number 
of comorbidities and HRQoL in RA patients. Disease activity was included as a covariate in the 
analysis because disease activity varies over time within individuals, which can influence reports 
of physical and mental HRQoL. 
2.2 Sample 
The parent study used convenience sampling and screened 645 adults with RA. Inclusion 
criteria for the current study included male or female adults with RA who were enrolled in the 
parent study and had complete data on disease activity, comorbidity, and physical and mental 
HRQoL variables at baseline. Of the 645 adults in the primary study, 590 adults had complete 
data for the variables of interest and were used as the participants for this secondary analysis. 
Only baseline data (labelled ADM NUM=0 in the database) were used in this analysis. 
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2.3 Measures 
The total number of comorbidities were determined based on participant’s responses in 
the self-administered Comorbidity Questionnaire developed by the Center for Research in 
Chronic Disorders at the University of Pittsburgh (Appendix A.1). A comorbidity was counted if 
a patient self-reported being diagnosed with the condition. Comorbidity count has been shown to 
correlate well (Spearman r=.90, p<0.001) with a rheumatoid disease comorbidity index across 
different races and ethnicities (Dowell et al., 2017). 
HRQoL was assessed by the physical component summary score (PCS) and mental 
component summary score (MCS) from the self-administered SF-36 (Appendix A.2). The PCS 
and MCS scores are normed to 50 (normal range 40-60), with higher scores indicating better 
HRQoL. The SF-36 is a non-disease specific quality of life instrument that, in diverse patient 
populations, has fair test-retest reliability (median r=.64 for patients reporting no change between 
baseline and 2-week administration interval), good internal consistency (median α=.80), and 
evidence of criterion-related and construct validity (McHorney, Ware, Lu, & Sherbourne, 1994; 
McHorney, Ware, & Raczek, 1993; McHorney, Ware, Rogers, Raczek, & Lu, 1992). The SF-36 
has been shown to be a valid and reliable indicator of HRQoL in the RA patient population, with 
validity established by its ability to discriminate between low, moderate, and high Disease 
Activity Score 28-joint count (DAS28) and with reliability established by Cronbach alpha>0.85 
for the separate scales (Linde, Sorensen, Ostergaard, Horslev-Petersen, & Hetland, 2008). The 
SF-36 contains eight scales: physical functioning, role functioning-physical, role functioning-
emotional, social functioning, bodily pain, mental health, vitality, and general health. PCS is 
composed of all eight scores with greater weight on physical functioning, role functioning-
physical, and bodily pain scores. MCS is composed of all eight scores, weighted more on mental 
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health, role functioning-emotional, and social functioning scores (Ware, Kosinski, & Keller, 
1994). 
Disease activity was assessed by a modified version of the self-administered Rapid 
Assessment of Disease Activity in Rheumatology (RADAR) questionnaire (Appendix A.3). The 
six-question RADAR assessment includes patient characterization of disease activity over the 
past six months, as well as current status of the following: joint tenderness and swelling, arthritis 
pain, morning stiffness, functional activity level, and pain in 10 specific joints on the left and 
right sides of the body. Patient RADAR scores on each question have been shown to correlate to 
clinician assessment (ICC=0.57 to 0.87 for specific scale items) and to correlate to change in 
joint status over six months (ICC=0.83) (Mason et al., 1992). The RADAR questionnaire has 
been criticized for the lack of a single summed score, requiring comparison of separate scores for 
each of the six questions (Fransen, Stucki, & van Riel, 2003). Previous studies have 
circumvented this issue by using partial sum scores from one or five of the RADAR questions. 
Nicassio used just the joint scores from RADAR Question 6 (4-point Likert scale on 10 joints on 
the left and right sides of the body, with a sum score of 0-60) as a marker of RA disease activity 
in a fatigue study (Nicassio et al., 2012). Stucki and colleagues summed five of the six RADAR 
questions (excluding the functional activity question) to form the Rheumatoid Arthritis Disease 
Activity Index (RADAI). Since the summed RADAI score has good internal consistency (α=0.91 
and 0.87 in studies with 55 and 484 patients, respectively) and good correlations with clinician 
assessment (Fransen, Langenegger, Michel, & Stucki, 2000; Stucki, Liang, Stucki, Bruhlmann, 
& Michel, 1995), the RADAI score was calculated and used in this study to assess disease 
activity. RADAI scores are standardized from 0-10, with higher scores indicating worse disease 
activity (Fransen et al., 2000). 
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2.4 Procedures 
In the parent study, participants received baseline questionnaires to complete and return 
by mail, which included the Comorbidity Questionnaire, SF-36, RADAR Questionnaire, and a 
sociodemographic questionnaire. For the current study, an expedited protocol was reviewed and 
approved by the University of Pittsburgh HRPO. The study investigator received only the 
required sociodemographic, comorbidity, disease activity, and HRQoL data listed by patient ID 
number, and consulted with a statistician to conduct the data analysis to answer the research 
questions. 
2.5 Data Analysis 
Data were analyzed using IBM® SPSS® Statistics version 26 (IBM Corp., Armonk, NY). 
The level of significance was set at 0.05, and 95% was used to estimate confidence intervals. 
First, the data were carefully screened for any irregularities (e.g., outliers, skewness, and 
kurtosis). For the variables of interest (PCS, MCS, Total Comorbidities, and RADAI), no outliers 
were identified, and skewness and kurtosis were within acceptable ranges (skewness ranged from 
-0.73 to 1.25, kurtosis ranged from -0.77 to 1.71). Second, categorical sociodemographic 
variables (e.g., race, marital status, household income, and education) were meaningfully 
categorized as appropriate. Descriptive statistics were summarized for the sociodemographic 
characteristics of the sample, the Total Comorbidities, the RADAI score, the PCS, and the MCS 
based on each variable’s level of measurement and observed data distribution. Third, participants 
with complete data in this sample were compared to those with missing data in the parent sample 
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on all variables using parametric two-sample t-tests for continuous level (ratio or interval scaled) 
variables and Chi-square tests of independence for nominal-scaled categorical variables. Internal 
consistency (Cronbach alpha) was assessed on the PCS and MCS of the SF-36. 
To answer the two research questions, partial correlations were performed on the 
association between Total Comorbidities and the two measures of HRQoL (PCS and MCS), 
while controlling for disease activity (RADAI). Additional analyses were conducted by repeating 
the correlation analysis without controlling for disease activity, and by performing partial 
correlations on the association of RADAI with the two measures of HRQoL (PCS and MCS) 
with and without controlling for Total Comorbidities. To test whether RADAI moderated the 
relationship between Total Comorbidities and HRQoL, regression models were run with Total 
Comorbidities, RADAI, and the interaction term as predictors for the two measures of HRQoL. 
To test whether RADAI mediated the relationship between Total Comorbidities and the two 
measures of HRQoL, the PROCESS macro for SPSS (Version 3.5) was downloaded and Model 
4 (a simple mediation model) was run within SPSS (Hayes, 2020). PROCESS is a modeling tool 
that uses bootstrapping to estimate the direct and indirect effects in mediation models (Appendix 
C). In this model, the total effect, “c”, is the extent to which Total Comorbidities influences 
HRQoL (PCS or MCS) in the absence of a mediator. The indirect effect is the extent to which 
the dependent variable (HRQoL) changes when the independent variable (Total Comorbidities) 
is constant and the mediating variable (RADAI) varies. The indirect effect is represented by 
variable “a*b”, where “a” is the effect of Total Comorbidities on Disease Activity (RADAI) and 
“b” is the effect of the mediator Disease Activity (RADAI) on HRQoL. The direct effect, “ c’ ”, 
measures the extent to which the dependent variable (HRQoL) changes when the mediator 
(RADAI) is constant and the independent variable (Total Comorbidities) changes. The total 
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effect “c” is the sum of the direct and indirect effects. The significance of the total, direct, and 
indirect effects were determined by computing the 95% confidence intervals of 5,000 
bootstrapped samples. The effects were considered significant if the 95% confidence interval did 
not include zero (Field, 2013; Hayes & Rockwood, 2016). 
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3.0 Results 
3.1 Demographic Characteristics of Sample 
A total of 645 subjects were screened in the parent study. Subject demographics are 
shown in Table 1. The majority of subjects were women (80%), white (92%), and non-Latino 
(96%). Subjects had a mean age of 59 years (SD=12), with a range of 19 to 85 years. Subjects 
were well educated with 19% completing a 2- or 4-year college degree, and 9% completing a 
graduate or professional degree. While most subjects were currently married (65%), a total of 
32% of subjects were never married, divorced, separated, or widowed. Household incomes were 
less than or equal to $30,000 for 43% of subjects, $30,001 to $50,000 for 22% of subjects, and 





Table 1 Parent Study Demographics (N=645) 
 
Demographic Characteristic  n (%) 
Sex   
Male  124 (19.2) 
Female  517 (80.2) 
Missing  4 (0.6) 
Age (years)  Mean = 59.3, Range = 19-85, SD = 11.9 
Race   
White  594 (92.1) 
Black or African American   24 (3.7) 
Asian  3 (0.5) 
Other (Including multi-racial and unknown)  12 (3.1) 
Missing  4 (0.6) 
Ethnicity   
Non-Latino  620 (96.2) 
Latino  6 (0.9) 
Missing  19 (2.9) 
Marital Status   
Never married  61 (9.4) 
Currently married  421 (65.3) 
Living with partner/significant other  13 (2.0) 
Widowed  85 (13.2) 
Separated  9 (1.4) 
Divorced  52 (8.1) 
Missing  4 (0.6) 
Highest Level of Education Completed   
Grade school  35 (5.4) 
High school or GED  300 (46.5) 
Vocational/Technical School  72 (11.2) 
2-year college  33 (5.1) 
4-year college  89 (13.8) 
Graduation/Professional School  58 (9.0) 
Other  54 (8.4) 
Missing  4 (0.6) 
Household Income   
≤ $10,000  37 (5.7) 
$10,001 to $13,000  37 (5.7) 
$13,001 to $20,000  87 (13.5) 
$20,001 to $30,000  119 (18.5) 
$30,001 to $50,000  140 (21.7) 
> $50,000  172 (26.7) 
Missing  53 (8.2) 
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3.2 Treatment of Missing Data 
Although 645 subjects were initially screened in the parent study, 55 subjects (8.5%) had 
missing data in the variables of interest (Total Comorbidities, PCS, MCS, and/or RADAI). As 
shown in Table 2, parametric two sample t-tests showed no significant differences in the 
variances and means for those with complete and those with missing data for the Total 
Comorbidities, PCS, and RADAI variables. For MCS, there was no significant difference in the 
variances for complete and missing data, but there was a significant difference in the means, with 
a p-value of 0.046 and a 95% confidence interval that did not include zero (0.060-5.884). The 
results of the Chi-Square analysis for the nominal-scaled variables are shown in Table 3. There 
were no significant differences for missing versus complete data for sex, race, marital status, 
education level, and household income. The mean age for those with complete data was 59.3 
years versus a mean age of 62.2 years for those with missing data, which was not significantly 
different (p=0.098). Since only 8.5% of the total data were missing for the variables of interest 
(55 of 645 subjects) and the mean of MCS was likely minimally affected with a p-value close to 
0.05, it was decided to proceed using only complete data for the analysis. 






t-test for Equality of Means 


















0.415 -0.157 0.988 1.425 0.155 2.492 0.115 
PCS1 0.518 -2.678 3.713 0.318 0.750 0.127 0.722 
MCS2 2.972 0.060 5.884 2.000 0.046 0.665 0.415 
RADAI3 -0.172 -0.954 0.611 -0.431 0.666 <0.001 0.984 
 
1 PCS (Physical Component Summary Score) from SF-36 HRQoL questionnaire 
2 MCS (Mental Component Summary Score) from SF-36 HRQoL questionnaire 
3 RADAI (Rheumatoid Arthritis Disease Activity Index) 
4 95% Confidence Interval on Mean Difference 
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Missing Data Chi-Square 
(p-Value) 
Sex   0.12 (p=0.73) 
Male 113 (91%) 11 (9%)  
Female 476 (92%) 41 (8%)  
Race   1.00 (p=0.32) 
White 562 (88%) 48 (7%)  
Non-white 27 (4%) 4 (1%)  
Marital Status   0.43 (p=0.51) 
Married 389 (61%) 32 (5%)  
Non-married 200 (31%) 20 (3%)  
Education level   2.92 (p=0.88) 
High school completed 514 (80%) 41 (6%)  
High school not completed 75 (12%) 11 (2%)  
Household Income   2.15 (p=0.14) 
Income above $30,001 293 (46%) 19 (3%)  
Income ≤ $30,000 254 (40%) 26 (4%)  
3.3 Data Distribution and Reliability 
The most common comorbidities were hypertension (n=218, 34%), anemia (n=131, 
21%), intermittent claudication (n=127, 20%), asthma (n=73, 11%), and arrhythmias (n=68, 
11%). Other comorbidities included heart attack (n=40, 6%), heart failure (n=42, 7%), coronary 
artery disease (n=43, 7%), valve disorders (n=38, 6%), other heart disorders (n=36, 6%), other 
blood disorders (n=19, 3%), emphysema (n=24, 4%), pneumonia (n=43, 7%), pulmonary fibrosis 
(n=12, 2%), and tuberculosis (n=2, <1%). The prevalence of most of these comorbidities were 
not significantly different compared to the general US population rates; however, asthma 
(p=0.027) and anemia (p<0.001) were significantly higher than the national rates (Seitz, Chen, & 
Lukacs, 2018; Villarroel et al., 2019a; Villarroel et al., 2019b). 
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Table 4 shows descriptive summary statistics for Total Comorbidities, PCS, MCS, and 
RADAI. The MCS mean score of 52.1 +/- 9.8 was within the normal range of 40-60, while the 
PCS mean score of 33.3 +/- 10.9 indicated a worse physical than mental HRQoL. The mean of 
Total Comorbidities was 1.4 and the mean of RADAI was 4.2, which imply the sample had 
relatively few comorbidities with low to moderate disease activity. Internal consistency of the 
PCS and MCS of the SF-36 was analyzed using Cronbach alpha. The Cronbach alpha for PCS, 
which heavily weights Physical Functioning, Role-Physical, Bodily Pain, and General Health, 
was 0.753. MCS, which heavily weights Vitality, Social Functioning, Role-Emotional, and 
Mental Health, had a Cronbach alpha of 0.714. These results indicated that PCS and MCS values 
had acceptable internal consistency reliability in measuring physical and mental HRQoL, 
respectively. 
 
Table 4 Descriptive Statistics for Variables of Interest (N=590) 
 
Variable Mean Standard Deviation Range 
Total Comorbidities 1.4 1.4 0-7 
PCS1 33.3 10.9 9.2-59.8 
MCS2 52.1 9.8 19.6-68.6 
RADAI3 4.2 2.2 0-9.9 
 
1 PCS (Physical Component Summary Score) from SF-36 HRQoL questionnaire 
2 MCS (Mental Component Summary Score) from SF-36 HRQoL questionnaire 
3 RADAI (Rheumatoid Arthritis Disease Activity Index) 
3.4 Results for Research Questions 
Table 5 addresses the research questions of whether the number of comorbidities is 
associated with physical and mental HRQoL (PCS and MCS, respectively) when controlling for 
disease activity (RADAI). When RADAI was the control variable, Total Comorbidities and PCS 
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were significantly but weakly negatively correlated (r=-0.228, p<0.001). When controlling for 
RADAI, Total Comorbidities and MCS were not significantly correlated (r=-0.041, p=0.315). 
When the correlation was rerun without RADAI as a controlling variable, the results showed 
slight improvements in the correlations between Total Comorbidities and PCS (r=-0.314, 
p<0.001) and MCS became significantly but very weakly negatively correlated (r=-0.098, 
p=0.017). Since the model correlation improved slightly and MCS became significant when 
RADAI was removed from the model, the relationship between RADAI and Total Comorbidities 
was further explored. 
 














RADAI4 Total Comorbidities -0.228 <0.001 -0.041 0.315 
None Total Comorbidities -0.314 <0.001 -0.098 0.017 
 
1 Pearsons zero-order correlation 
2 PCS (Physical Component Summary Score) from SF-36 HRQoL questionnaire 
3 MCS (Mental Component Summary Score) from SF-36 HRQoL questionnaire 
4 RADAI (Rheumatoid Arthritis Disease Activity Index) 
 
First, a correlation was performed with no control variable and with PCS, MCS, and 
RADAI as dependent variables. As seen in Table 6, Total Comorbidities was weakly but 
significantly positively correlated with RADAI (r=0.226, p<0.001), suggesting more 
comorbidities occur in those with more disease activity. When Total Comorbidities was used as 
the controlling variable and RADAI was the independent variable, the correlations slightly 





Table 6 Correlation Analysis of Comorbidities, RADAI and PCS/MCS (N=590) 
 
Control Variable Variable of Interest  PCS1 MCS2 RADAI3 

























1 PCS (Physical Component Summary Score) from SF-36 HRQoL questionnaire 
2 MCS (Mental Component Summary Score) from SF-36 HRQoL questionnaire 
3 RADAI (Rheumatoid Arthritis Disease Activity Index) 
 
The role of RADAI in the association between Total Comorbidities and HRQoL was 
further explored by testing if RADAI moderated or mediated the relationship between Total 
Comorbidities and HRQoL. The results of the moderation analysis with an interaction term for 
Total Comorbidities*RADAI are shown in Table 7 for PCS and Table 8 for MCS, respectively. 
The interaction term was not significant for PCS (p=0.093) or MCS (p=0.504), suggesting that 
RADAI does not moderate the relationship between Total Comorbidities and HRQoL. 
 









(Constant) 47.7 0.991 - 48.2 <0.001 
RADAI1 -3.0 0.225 -0.615 -13.4 <0.001 
Total Comorbidities -2.3 0.568 -0.298 -4.0 <0.001 
Interaction term (Total 
Comorbidities * RADAI1) 
0.2 0.112 0.145 1.7 0.093 
 
1 RADAI (Rheumatoid Arthritis Disease Activity Index) 
2 Unstandardized Beta from regression: Slope of line between predictor and dependent variable 
3 Unstandardized Standard Deviation: Standard error for Unstandardized Beta above 
















(Constant) 56.7 1.115 - 50.8 <0.001 
RADAI1 -1.0 0.253 -0.227 -4.0 <0.001 
Total Comorbidities 0.1 0.639 0.014 0.2 0.879 
Interaction term (Total 
Comorbidities * RADAI1) 
-0.1 0.127 -0.072 -0.7 0.504 
 
1 RADAI (Rheumatoid Arthritis Disease Activity Index) 
2 Unstandardized Beta from regression: Slope of line between predictor and dependent variable 
3 Unstandardized Standard Deviation: Standard error for Unstandardized Beta above  
4 Standardized Beta: on scale of -1 to 1 
 
The preconditions to conduct a mediation analysis were that Total Comorbidities had to 
predict both dependent variables (PCS and MCS), as well as the potential mediating variable 
(RADAI). The first line in Table 6 shows that this precondition was met, as Total Comorbidities 
was significantly correlated with PCS (p<0.001), MCS (p =0.017), and RADAI (p<0.001). 
The mediation effect was analyzed using the PROCESS macro to estimate the total effect 
(not considering any mediator), direct effect (effect of Total Comorbidities on HRQoL 
controlling for RADAI) and indirect effect (mediation effect of Total Comorbidities on HRQoL 
via RADAI). Table 9 shows the results for the mediation of RADAI on the effect of Total 
Comorbidities on PCS. Total Comorbidities had a significant and negative total effect on PCS 
when RADAI was not considered (p<0.001). Total Comorbidities also had a significant negative 
direct effect on PCS when controlling for RADAI (p<0.001). The indirect effect via RADAI as a 
mediating variable was also considered significant because the bootstrapped 95% confidence 
interval of -1.3593 to -0.6152 did not contain zero. The results in Table 9 indicate that RADAI is 
a mediator for the association between Total Comorbidities and PCS, and that it increases the 
significant negative relationship between them. 
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Total effect (c)1 -2.4119 0.3010 -8.0121 <0.001 -3.0031 -1.8207 
Direct effect (c’)2 -1.4378 0.2530 -5.6832 <0.001 -1.9347 -0.9409 
Indirect effect via 
RADAI (a*b)3 
-0.9740 0.1851* - - -1.3593* -0.6152* 
Effect of RADAI on 
PCS (b)4 
-2.7359 0.1606 - - -3.0513 -2.4205 
Effect of Total 
Comorbidities on 
RADAI (a)5 
0.3560 - - - - - 
 
1 Total effect (c) not considering RADAI as mediator 
2 Direct effect (c’) holding RADAI constant and varying Total Comorbidities 
3 Indirect effect (a*b) via RADAI, holding Total Comorbidities constant and varying RADAI 
4 b is effect of RADAI on PCS (Physical Component Score) 
5 a is effect of Total Comorbidities on RADAI where a=a*b/b 
6 95% Confidence Intervals 
* Bootstrapped 95% Confidence Intervals 
 
Table 10 shows the results for the mediation of RADAI on the association between Total 
Comorbidities and MCS. While Total Comorbidities had a significant and negative total effect 
on MCS (p=0.0167), it did not have a significant direct effect (p=0.3153). Since the bootstrapped 
95% confidence intervals of -0.0607 to -0.0328 for the indirect effect via RADAI did not include 
zero, Table 10 shows that RADAI was a significant negative mediator of the association between 


















Total effect (c)1 -0.6856 0.2857 -2.4 0.0167 -1.2467 -0.1245 
Direct effect(c’)2 -0.2857 0.2843 1.0050 0.3153 -0.8441 0.2726 
Indirect effect via 
RADAI (a*b)3 
-0.4000 0.0096 - - -0.0607*  -0.0328* 
Effect of RADAI 
on PCS (b)4 
-1.1233 0.1804 -6.2253 <0.001 -1.4777 -0.7689 
Effect of Total 
Comorbidities on 
RADAI (a)5 
0.3560 - - - - - 
 
1 Total effect (c) not considering RADAI as mediator 
2 Direct effect (c’) holding RADAI constant and varying Total Comorbidities 
3 Indirect effect (a*b) via RADAI holding Total Comorbidities constant and varying RADAI 
4 b is effect of RADAI on MCS (Mental Component Score) 
5 a is effect of Total Comorbidities on RADAI where a=a*b/b 
6 95% Confidence Intervals 




4.1 Demographics and Variables of Interest 
The majority of subjects in this study were white (92.1%) women (80.2%) with a mean 
age of 59 years. This sample was relatively representative of the general RA population, as it 
most commonly affects Caucasian (64.2%) women (77.8%) and prevalence increases with age. 
However, Caucasians were overrepresented in the study (92.1% versus 64.2%), which led to 
other races being underrepresented. Only 4% of subjects were Black/African American, less than 
1% were Asian, and 1% were Latino/Hispanic. Although Black/American Americans, Asian, and 
Hispanic patients are less likely to be diagnosed with RA compared to Caucasian patients, they 
make up more of the RA population than represented in this study (Kawatkar, Portugal, Chu, & 
Iyer, 2012). Additionally, Black/African American and Hispanic patients are more likely to be 
severely impacted by the disease due to health disparities and genetics. Hispanic patients often 
have higher levels of disease activity compared to other groups, even with higher uses of 
biologic treatments. Both Black/African American and Hispanic RA patients report worse 
functional status compared to Caucasian patients (Greenberg et al., 2013). 
The prevalence of different comorbidities in this study were relatively representative of 
those reported for the RA population with hypertension as the most common comorbidity (34% 
versus reported 39%). Coronary artery disease had a similar prevalence (7% versus reported 5%) 
but asthma did not occur as frequently in this study as reported in the RA population (11% 
versus reported 21%) (Dougados et al., 2013). The mean Total Comorbidities in this study (1.4 
+/- 1.4) was similar to the mean of 1.6 comorbidities reported in 17,738 patients (Wolfe & 
Michaud, 2008). The RADAI (4.2 out of 10) score in this study suggests the population had low 
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to moderate disease compared to the general RA population. The mean PCS (33.3 +/- 10.9) and 
MCS (52.1 +/- 9.8) in the study were slightly higher (implying better HRQoL) than the mean 
PCS (29-33) and mean MCS (41-51) reported for US studies with similar numbers of RA 
patients (Strand, Burmester et al., 2012; Strand, Sharp et al., 2012). 
4.2 Research Questions: Association of Total Comorbidities with HRQoL Measures 
When controlling for disease activity (RADAI) in this study, Total Comorbidities had 
weak negative associations with both measures of HRQoL (PCS and MCS), but only PCS was 
significant (p<0.001). A significant association of PCS but not MCS with RA disease activity 
was seen in a large tociluzimab study, although Total Comorbidities was not measured (Strand, 
Burmester et al., 2012). The greater influence on PCS than MCS may be partially explained by 
the orthogonal weighting calculation applied to the SF-36 domains to calculate the normed PCS 
and MCS scores. In the calculation, three mental scores (SF: social functioning, RE: role 
limitations due to emotional problems, and MH: mental health) have negative weighting on PCS. 
Three physical scores (PF: physical functioning, RP: role limitations due to physical health 
problems, and BP: bodily pain) have negative weighting on MCS. For diseases with considerable 
physical burden like RA, the net effect of the negative weighting for three physical scores raises 
the MCS (Laucis, Hays, & Bhattacharyya, 2015). This scoring effect may underestimate the 
actual mental HRQoL burden as well as decrease the likelihood of detecting significant changes 
in MCS in RA patients. Figure 1 compares the means for the eight normed SF-36 domains in this 
study to the US means for a population of healthy women with a mean age of 62 years (Yost, 
Haan, Levine, & Gold, 2005). All eight domains in this study were lower than in healthy women 
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of a similar age, but the most significant impacts on HRQoL were in the four physical domains 
and vitality, with lesser impacts on mental health, role limitations due to emotional problems, 
and social functioning. This finding suggests that overall HRQoL was lower for this RA 
population than for healthy peers, with physical HRQoL being more severely impacted than 
mental HRQoL. 
Figure 1 Mean of Normed SF-36 Domains for Study Sample versus US Females 
 
 
In this study, higher number of Total Comorbidities were significantly associated with 
greater disease activity as measured by RADAI (p<0.001). In fact, when controlling for Total 
Comorbidities, disease activity was significantly negatively correlated with both PCS and MCS 
(p<0.001). The stronger association of disease activity (RADAI) than Total Comorbidities with 
both measures of HRQoL raised the possibility that disease activity (RADAI) could be 
moderating or mediating the association between the Total Comorbidities and HRQoL. RADAI 
did not act as a moderator, but analysis via PROCESS showed it was acting as a mediator in the 
relationship between Total Comorbidities and the two measures of HRQoL (PCS and MCS). 
Physical component summary score (PCS): Physical Functioning, Role-Physical, Bodily Pain, General Health 
Mental component summary score (MCS): Vitality, Social Functioning, Role-Emotional, Mental Health 
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Figure 2 shows a model of RADAI as a mediator of the association between Total 
Comorbidities and PCS using the PROCESS effects values. The significant indirect effect via 
RADAI from Table 9 (-0.9740, bootstrapped 95% confidence interval of -1.3593 to -0.6152) was 
the product of the significant positive effect of Total Comorbidities on RADAI (0.3560, 
p<0.001) and the significant negative effect of RADAI on PCS (-2.7359, p<0.001). The direct 
effect of Total Comorbidities on PCS (-1.4378, p<0.001) was significant but considerably 
reduced compared to the total effect (-2.4119, p<0.001), showing the RADAI mediation effect. 
The results indicate that patients with more total comorbidities tend to have decreased physical 
functioning, which is further exacerbated by increases in disease activity. 
 




a is effect of Total Comorbidities on Disease Activity (RADAI) 
b is effect of mediator, Disease Activity (RADAI), on PCS 
a*b (not shown in Figure) is indirect effect of mediator, Disease Activity, on PCS where a*b = 
(0.3560*-2.7359) = -0.9740 
c is total effect of Total Comorbidities on PCS 
c’ is direct effect of Total Comorbidities on PCS, calculated by c’ = (c - indirect effect a*b) 
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Figure 3 showed RADAI’s mediation of the relationship between Total Comorbidities 
and MCS. The significant indirect effect of RADAI shown in Table 10 (-0.4000, bootstrapped 
95% confidence interval of -0.0607 to -0.0328) was the product of the significant positive effect 
of Total Comorbidities on RADAI (0.3560, p<0.001) and the significant negative effect of 
RADAI on MCS (-1.1233, p<0.001). Although the total effect of number of Total Comorbidities 
on MCS (-0.6856, p=0.0167) was significant, when it was reduced by the mediation effect of 
RADAI, the direct effect was not significant (-0.2857, p=0.3153). As with PCS, as the number of 
Total Comorbidities increased, disease activity (RADAI) increased. As disease activity 
increased, the MCS measure of HRQoL decreased. However, for MCS, RADAI more 
completely mediated the relationship, so that there was no significant direct effect of Total 
Comorbidities on the MCS measure of HRQoL. 
Figure 3 Mediation Model for MCS (Mental Component Summary Score from SF-36) 
 
a is effect of Total Comorbidities on Disease Activity (RADAI) 
b is effect of mediator, Disease Activity (RADAI), on MCS 
a*b (not shown in Figure) is indirect effect of mediator, Disease Activity, on MCS where a*b = 
(0.3560*-1.1233) = -0.4000 
c is total effect of Total Comorbidities on MCS 
c’ is direct effect of Total Comorbidities on MCS, calculated by c’= (c - indirect effect a*b) 
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Comparing Figure 2 and Figure 3, RADAI had a stronger effect on the physical 
component summary score (PCS) than the mental component summary score (MCS) of HRQoL 
(-2.7359 vs -1.1233, respectively). This implies that as disease activity (RADAI) became more 
severe, PCS worsened more than MCS. Total Comorbidities also had a stronger direct effect on 
PCS than MCS (-1.4378 vs -0.2857, respectively), which implies that with increasing Total 
Comorbidities, PCS worsens more than MCS. As noted previously, the weighted calculation of 
HRQoL component scores may artificially raise the MCS in physically burdensome diseases like 
RA (Laucis et al., 2015), but the comparison with the individual HRQoL domains in Figure 1 
supports the conclusion that the RA disease activity and total comorbidities had a stronger effect 
on physical than mental HRQoL. 
4.3 Implications 
The significant direct association between increases in Total Comorbidities and decreases 
in the physical component summary score of HRQoL in this study shows the importance of 
preventing, monitoring, and treating common comorbidities in RA. This finding is particularly 
important for comorbidities directly related to RA, such as cardiovascular complications and 
anemia. Effective treatment of RA is also very important, since increases in disease activity are 
associated with decreased HRQoL physical and mental component summary scores. 
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4.4 Research Next Steps 
There are several results from this study that could be further investigated in future 
studies. The demographics of those involved in the study were skewed towards white, well-
educated, married women with low-moderate disease activity and relatively few comorbidities. 
Although RA is more prevalent in women, the demographics are not fully representative of the 
RA population. It would be interesting to compare these results with subjects of a lower 
socioeconomic status with similar or greater disease activity to see if MCS is more affected by 
Total Comorbidities in patients who have lower income, and less resources/treatment options. It 
would also be interesting to include more subjects from different races or ethnicities, especially 
those who are Black or Hispanic, as these individuals are more likely to have lower reported 
functional ability in RA, as well as the presence of health disparities. These disparities could 
further impact their ability to treat comorbidities and RA, and could lead to worsening disease 
activity, physical health, and mental health. 
4.5 Limitations 
As stated above, the lack of demographic diversity is a limitation of this study and more 
diverse racial, ethnic, and socioeconomic groups could be further investigated in future studies. 
Additionally, patients in this study had relatively low Total Comorbidities (mean=1.4) and low-
moderate disease activity (mean=4.2), which might have limited the ability to detect changes in 
the mental component summary score of HRQoL. Another limitation is that this study was 
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conducted prior to the wider use of biologic DMARDs. It is also important to note that the 




This study explored if the number of Total Comorbidities in patients with RA was 
associated with HRQoL through physical (PCS) and mental (MCS) domains when controlling 
for disease activity (RADAI). When controlled for disease activity, increases in the number of 
Total Comorbidities led to significant decreases in physical HRQoL, but not mental HRQoL. 
With no control for disease activity, the number of Total Comorbidities appeared to have a better 
correlation to physical and mental HRQoL, with both significantly decreasing with increasing 
Total Comorbidities. Disease activity was found to be a significant mediator of the relationship 
between the number of Total Comorbidities and both physical and mental HRQoL. When the 
mediating effect of disease activity was removed, the number of Total Comorbidities was still 
significantly and negatively correlated with physical HRQoL. Although number of comorbidities 
appeared to be significantly negatively correlated with mental HRQoL based on the Total Effect 
model, this result was largely due to the mediating effect of disease activity. When disease 
activity was removed from the model, the direct effect of Total Comorbidities on mental HRQoL 
was no longer significant. The results of this study indicate that, when including disease activity 
as a mediating variable, there is a direct association between comorbidities and physical HRQoL. 
When the number of Total Comorbidities increased, the physical HRQoL of a patient decreased. 
As the number Total Comorbidities increased, the mental HRQoL is not significantly directly 
affected, as most of the apparent effect is due to the mediating effect of disease activity. These 
results emphasize the importance of treating the patient’s comorbidities, in addition to their 
primary disease, in order to improve their physical HRQoL. 
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Appendix A Assessment Instruments 
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